Announcements Trials
Browse Landscape

Status

Completed 22Terminated 9Active not recruiting 9Recruiting 4No longer available 1Available 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 1

Interventions

nilotinib 4dabrafenib 4trametinib 3regorafenib 3midostaurin 3elotuzumab 3Nivolumab 3tazemetostat 2talimogene laherparepvec 2ceritinib 2TIC10 compound 2Suspensions 2Prednisone 2Powders 2Panobinostat 2Melphalan 2Lenalidomide 2Ipilimumab 2Everolimus 2Dexamethasone 2Crizotinib 2Bortezomib 2Bevacizumab 2Axitinib 2zanubrutinib 1zanidatamab 1venetoclax 1veliparib 1tucatinib 1talquetamab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
No longer available × INDUSTRY × Alpelisib × Clear all
NCT03706573 2021-07-19

Managed Access Program to Provide Alpelisib for Patients With HR+ Advanced or Metastatic Breast Cancer

Novartis

No longer available
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡